サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1298406

筋骨格系障害治療薬市場：薬剤タイプ別、投与経路別、流通チャネル別：世界市場機会分析と産業予測、2023-2032年

Musculoskeletal Disorders Drugs Market By Drug Type, By Route of Administration, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日: | 発行: Allied Market Research | ページ情報: 英文 263 Pages | 納期: 2～3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
筋骨格系障害治療薬市場：薬剤タイプ別、投与経路別、流通チャネル別：世界市場機会分析と産業予測、2023-2032年
出版日: 2023年04月01日
発行: Allied Market Research
ページ情報: 英文 263 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

筋骨格系障害治療薬市場は、2022年に834億7,424万米ドルと評価され、2032年には1,260億3,022万米ドルに達すると推定され、2023年から2032年までのCAGRは4.2%です。

Musculoskeletal Disorders Drugs Market-IMG1

筋骨格系障害（MSD）は筋肉、骨、関節に影響を及ぼします。これらの障害は、身体の様々な部分に痛み、こわばり、腫れを引き起こし、日常生活を送る能力に影響を与えます。筋骨格系障害の症状には、関節のこわばり、腫れ、鈍痛などがあります。これらの障害は、反復運動、ぎこちない姿勢、長時間の座りっぱなしや立ちっぱなしなど、さまざまな要因によって引き起こされます。MSDはあらゆる年齢層の人々に影響を及ぼしますが、高齢者や、スポーツ選手や肉体労働者など、筋骨格系に負担をかけるような身体活動を行っている人に多く見られます。最も一般的な筋骨格系障害には、関節リウマチ、骨粗鬆症、変形性関節症、線維筋痛症などがあります。

筋骨格系障害治療薬は、筋肉、骨、関節に影響を及ぼす疾患の治療に使用される薬剤の一種です。これらの薬剤は、関節リウマチ、骨粗鬆症、線維筋痛症などの筋骨格系障害に伴う痛み、炎症、こわばりを緩和するのに役立ちます。筋骨格系薬剤には、鎮痛薬、コルチコステロイド、疾患修飾性抗リウマチ薬、コルチコステロイドなどいくつかの種類があります。

関節リウマチ、骨粗鬆症、強直性脊椎炎などの筋骨格系障害の有病率の増加、筋骨格系障害の治療に対する意識の高まりが、市場成長の要因です。労働時間の延長や運動量の増加といったライフスタイルの変化は、運動器障害の発生率の増加をもたらしています。このため、これらの症状を効果的に管理できる薬剤に対する需要が高まると予想されます。例えば、オーストラリア保健福祉研究所によると、2020年には5人に3人が変形性関節症と診断されると報告されています。さらに、筋骨格障害に罹患しやすい老年人口が増加しているため、これらの症状を管理する薬剤に対する需要が高まり、市場の成長をさらに促進する結果となっています。しかし、低開発国では治療が受けられないため、市場成長の妨げになると予想されます。

さらに、生物学的製剤やバイオシミラーを含む筋骨格系障害の新薬の開発により、治療オプションの有効性と安全性が向上しました。このため、これらの薬剤に対する需要が増加しています。さらに、筋骨格系障害に対する人々の意識が高まり、これらの症状に対する診察や治療を求める患者が増加したことも、市場の成長を支えています。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主な調査結果
    • 影響要因
    • 主な投資機会
  • ポーターのファイブフォース分析
    • 供給企業の交渉力
    • 買い手の交渉力
    • 代替品の脅威
    • 新規参入業者の脅威
    • 競合の激しさ
  • 市場力学
    • 促進要因
      • 筋骨格系（MSK）障害の高い有病率
      • 世界の老年人口の急増
      • パイプライン医薬品の増加
    • 阻害要因
      • 新興国における治療不足
    • 機会
      • 新興市場における高い成長の可能性
  • COVID-19市場への影響分析

第4章 筋骨格系障害治療薬市場：薬剤タイプ別

  • 概要
    • 市場規模および予測
  • 鎮痛薬
    • 主要市場動向、成長要因、機会
    • 市場規模および予測：地域別
    • 市場シェア分析：国別
  • DMARDs（抗悪性腫瘍剤）
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • コルチコステロイド
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • その他
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別

第5章 筋骨格系障害治療薬市場：投与経路別

  • 概要
    • 市場規模および予測
  • 経口
    • 主要市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • 非経口
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別

第6章 筋骨格系障害治療薬市場：流通チャネル別

  • 概要
    • 市場規模と予測
  • 病院薬局
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • オンラインプロバイダー
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • ドラッグストアと小売薬局
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別

第7章 筋骨格系障害治療薬市場：地域別

  • 概要
    • 市場規模・予測： 地域別
  • 北米
    • 主要動向と機会
    • 市場規模・予測：薬物タイプ別
    • 市場規模・予測：投与経路別
    • 市場規模・予測：流通チャネル別
    • 市場規模・予測：国別
      • 米国
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬剤タイプ別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
      • カナダ
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬剤タイプ別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
      • メキシコ
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬物タイプ別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
  • 欧州
    • 主要動向と機会
    • 市場規模・予測：薬物タイプ別
    • 市場規模・予測：投与経路別
    • 市場規模・予測：流通チャネル別
    • 市場規模・予測：国別
      • ドイツ
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬剤タイプ別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
      • フランス
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬剤タイプ別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
      • 英国
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬剤タイプ別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
      • イタリア
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬剤タイプ別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
      • スペイン
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬剤タイプ別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
      • その他欧州
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬剤タイプ別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
  • アジア太平洋地域
    • 主要動向と機会
    • 市場規模・予測：薬物タイプ別
    • 市場規模・予測：投与経路別
    • 市場規模・予測：流通チャネル別
    • 市場規模・予測：国別
      • 日本
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬剤タイプ別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
      • 中国
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬剤タイプ別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
      • オーストラリア
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬剤タイプ別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
      • インド
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬剤タイプ別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
      • 韓国
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬剤タイプ別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
      • その他アジア太平洋地域
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬剤タイプ別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
  • ラテンアメリカ・中東・アフリカ
    • 主要動向と機会
    • 市場規模・予測：薬剤タイプ別
    • 市場規模・予測：投与経路別
    • 市場規模・予測：流通チャネル別
    • 市場規模・予測：国別
      • ブラジル
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬剤タイプ別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
      • サウジアラビア
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬剤タイプ別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
      • 南アフリカ
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬物タイプ別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別
      • その他の地域
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬剤タイプ別
      • 市場規模・予測：投与経路別
      • 市場規模・予測：流通チャネル別

第8章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • トップ企業のポジショニング、2022年

第9章 企業プロファイル

  • AbbVie Inc.
  • Amgen Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • UCB S.A.
図表

LIST OF TABLES

  • TABLE 01. GLOBAL MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 02. MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR ANALGESICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR DMARDS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR CORTICOSTEROIDS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 06. GLOBAL MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 07. MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR PARENTERAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. GLOBAL MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 10. MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 18. U.S. MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 19. U.S. MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 20. U.S. MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 21. CANADA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 22. CANADA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 23. CANADA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 24. MEXICO MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 25. MEXICO MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 26. MEXICO MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 27. EUROPE MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 28. EUROPE MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 31. GERMANY MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 32. GERMANY MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 33. GERMANY MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 34. FRANCE MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 35. FRANCE MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 36. FRANCE MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 37. UK MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 38. UK MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 39. UK MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 40. ITALY MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 41. ITALY MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 42. ITALY MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 43. SPAIN MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 44. SPAIN MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 45. SPAIN MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 46. REST OF EUROPE MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 47. REST OF EUROPE MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 48. REST OF EUROPE MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 49. ASIA-PACIFIC MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 50. ASIA-PACIFIC MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 51. ASIA-PACIFIC MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 52. ASIA-PACIFIC MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 53. JAPAN MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 54. JAPAN MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 55. JAPAN MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 56. CHINA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 57. CHINA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 58. CHINA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 59. AUSTRALIA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 60. AUSTRALIA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 61. AUSTRALIA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 62. INDIA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 63. INDIA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 64. INDIA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 65. SOUTH KOREA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 66. SOUTH KOREA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 67. SOUTH KOREA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 68. REST OF ASIA-PACIFIC MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 71. LAMEA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 72. LAMEA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 73. LAMEA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 74. LAMEA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 75. BRAZIL MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 76. BRAZIL MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 77. BRAZIL MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 78. SAUDI ARABIA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 79. SAUDI ARABIA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 80. SAUDI ARABIA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 81. SOUTH AFRICA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 82. SOUTH AFRICA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 83. SOUTH AFRICA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 84. REST OF LAMEA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 85. REST OF LAMEA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 86. REST OF LAMEA MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 87. ABBVIE INC.: KEY EXECUTIVES
  • TABLE 88. ABBVIE INC.: COMPANY SNAPSHOT
  • TABLE 89. ABBVIE INC.: PRODUCT SEGMENTS
  • TABLE 90. ABBVIE INC.: PRODUCT PORTFOLIO
  • TABLE 91. ABBVIE INC.: KEY STRATERGIES
  • TABLE 92. AMGEN INC.: KEY EXECUTIVES
  • TABLE 93. AMGEN INC.: COMPANY SNAPSHOT
  • TABLE 94. AMGEN INC.: PRODUCT SEGMENTS
  • TABLE 95. AMGEN INC.: PRODUCT PORTFOLIO
  • TABLE 96. AMGEN INC.: KEY STRATERGIES
  • TABLE 97. ELI LILLY AND COMPANY: KEY EXECUTIVES
  • TABLE 98. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 99. ELI LILLY AND COMPANY: PRODUCT SEGMENTS
  • TABLE 100. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 101. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 102. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 103. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
  • TABLE 104. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 105. JOHNSON & JOHNSON: KEY EXECUTIVES
  • TABLE 106. JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • TABLE 107. JOHNSON & JOHNSON: PRODUCT SEGMENTS
  • TABLE 108. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
  • TABLE 109. JOHNSON & JOHNSON: KEY STRATERGIES
  • TABLE 110. MERCK & CO., INC.: KEY EXECUTIVES
  • TABLE 111. MERCK & CO., INC.: COMPANY SNAPSHOT
  • TABLE 112. MERCK & CO., INC.: PRODUCT SEGMENTS
  • TABLE 113. MERCK & CO., INC.: PRODUCT PORTFOLIO
  • TABLE 114. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 115. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 116. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 117. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 118. NOVARTIS AG: KEY STRATERGIES
  • TABLE 119. PFIZER INC.: KEY EXECUTIVES
  • TABLE 120. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 121. PFIZER INC.: PRODUCT SEGMENTS
  • TABLE 122. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 123. PFIZER INC.: KEY STRATERGIES
  • TABLE 124. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 125. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 126. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
  • TABLE 127. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 128. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
  • TABLE 129. UCB S.A.: KEY EXECUTIVES
  • TABLE 130. UCB S.A.: COMPANY SNAPSHOT
  • TABLE 131. UCB S.A.: PRODUCT SEGMENTS
  • TABLE 132. UCB S.A.: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. MUSCULOSKELETAL DISORDERS DRUGS MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF MUSCULOSKELETAL DISORDERS DRUGS MARKET, 2022-2032
  • FIGURE 03. TOP INVESTMENT POCKETS IN MUSCULOSKELETAL DISORDERS DRUGS MARKET (2023-2032)
  • FIGURE 04. HIGH BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 06. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 07. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 08. MODERATE INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALMUSCULOSKELETAL DISORDERS DRUGS MARKET
  • FIGURE 10. MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE, 2022(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR ANALGESICS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR DMARDS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR CORTICOSTEROIDS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR ORAL, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR PARENTERAL, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF MUSCULOSKELETAL DISORDERS DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 22. MUSCULOSKELETAL DISORDERS DRUGS MARKET BY REGION, 2022
  • FIGURE 23. U.S. MUSCULOSKELETAL DISORDERS DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 24. CANADA MUSCULOSKELETAL DISORDERS DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. MEXICO MUSCULOSKELETAL DISORDERS DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. GERMANY MUSCULOSKELETAL DISORDERS DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. FRANCE MUSCULOSKELETAL DISORDERS DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. UK MUSCULOSKELETAL DISORDERS DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. ITALY MUSCULOSKELETAL DISORDERS DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. SPAIN MUSCULOSKELETAL DISORDERS DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. REST OF EUROPE MUSCULOSKELETAL DISORDERS DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. JAPAN MUSCULOSKELETAL DISORDERS DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. CHINA MUSCULOSKELETAL DISORDERS DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. AUSTRALIA MUSCULOSKELETAL DISORDERS DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. INDIA MUSCULOSKELETAL DISORDERS DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. SOUTH KOREA MUSCULOSKELETAL DISORDERS DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. REST OF ASIA-PACIFIC MUSCULOSKELETAL DISORDERS DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. BRAZIL MUSCULOSKELETAL DISORDERS DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. SAUDI ARABIA MUSCULOSKELETAL DISORDERS DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. SOUTH AFRICA MUSCULOSKELETAL DISORDERS DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. REST OF LAMEA MUSCULOSKELETAL DISORDERS DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 45. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 46. COMPETITIVE DASHBOARD
  • FIGURE 47. COMPETITIVE HEATMAP: MUSCULOSKELETAL DISORDERS DRUGS MARKET
  • FIGURE 48. TOP PLAYER POSITIONING, 2022
  • FIGURE 49. ABBVIE INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 50. ABBVIE INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 51. ABBVIE INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 52. AMGEN INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 53. AMGEN INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 54. ELI LILLY AND COMPANY: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 55. ELI LILLY AND COMPANY: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 56. F. HOFFMANN-LA ROCHE LTD.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 57. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 58. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 59. JOHNSON & JOHNSON: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 60. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 61. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 62. MERCK & CO., INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 63. MERCK & CO., INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 64. MERCK & CO., INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 65. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 66. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 67. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 68. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 69. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 70. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 71. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 72. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 73. UCB S.A.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 74. UCB S.A.: REVENUE SHARE BY REGION, 2022 (%)
目次
Product Code: A13212

The musculoskeletal disorders drugs market valued for $83,474.24 million in 2022 and is estimated to reach $126,030.22 million by 2032, exhibiting a CAGR of 4.2% from 2023 to 2032.

Musculoskeletal Disorders Drugs Market - IMG1

Musculoskeletal disorders (MSDs) affect the muscles, bones, and joints. These disorders cause pain, stiffness, and swelling in various parts of the body and they affect an ability of a person to perform daily activities. The symptoms of musculoskeletal disorders include stiff joints, swelling, and dull aches. These disorders may be caused by a variety of factors including repetitive motions, awkward postures, prolonged sitting or standing. MSDs affect people of all ages, but they are more common among the elderly and those who engage in physical activities that have stress on the musculoskeletal system, such as athletes and manual laborers. Some of the most common musculoskeletal disorders include rheumatoid arthritis, osteoporosis, osteoarthritis, and fibromyalgia.

Musculoskeletal disorders drugs are a class of medications that are used to treat conditions affecting the muscles, bones, joints of body. These drugs help to alleviate pain, inflammation, and stiffness associated with musculoskeletal disorders such as rheumatoid arthritis, osteoporosis, and fibromyalgia. There are several types of musculoskeletal drugs including analgesics, corticosteroids, disease modifying anti rheumatic drugs, and corticosteroids.

Increase in prevalence of musculoskeletal disorders such as rheumatoid arthritis osteoporosis, and ankylosing spondylitis, and surge in awareness toward availability of treatment for musculoskeletal disorders are the factors that contribute towards the growth of the market. Changes in lifestyle, such as longer working hours and increased physical activity, have resulted in a higher incidence of musculoskeletal disorders. This is anticipated to increase the demand for drugs that can effectively manage these conditions. For instance, according to Australian Institute of Health and Welfare, in 2020, it was reported that 3 in 5 individuals diagnosed with osteoarthritis. In addition, rise in geriatric population as they are more susceptible to musculoskeletal disorders, which resulted in a higher demand for drugs to manage these conditions and further drive the market growth. However, lack of access to treatment in underdeveloped countries, is expected to hamper the market growth.

Moreover, the development of new drugs for musculoskeletal disorders, including biologics and biosimilars, has improved the efficacy and safety of treatment options. This led to an increase in the demand for these drugs. In addition, increase in awareness of musculoskeletal disorders among population, which led to more patients seeking medical attention and treatment for these conditions which supports the market growth.

The global musculoskeletal disorders drugs market is segmented into drug type, route of administration, distribution channel, and region. On the basis of drug type, the market is categorized into analgesics, DMARDs, corticosteroids, and others. On the basis of route of administration, the market is bifurcated into oral, and parenteral. On the basis of distribution channel, the market is classified into hospital pharmacies, online providers, and drug stores & retail pharmacies. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).

Major key players that operate in the global musculoskeletal disorders drugs market are: AbbVie Inc., Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd. and UCB S.A. Key players operating in the market have adopted product launch, and product approval as their key strategies to expand their product portfolio. For instance, in June 2022, Amgen announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI (rituximab-arrx), a biosimilar to Rituxan, in combination with methotrexate for adults with moderate to severely active rheumatoid arthritis.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the musculoskeletal disorders drugs market analysis from 2022 to 2032 to identify the prevailing musculoskeletal disorders drugs market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the musculoskeletal disorders drugs market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global musculoskeletal disorders drugs market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Type

  • Analgesics
  • DMARDs
  • Corticosteroids
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Hospital Pharmacies
  • Online Providers
  • Drug Stores and Retail Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • AbbVie Inc.
    • Amgen Inc.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • Johnson & Johnson
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.
    • UCB S.A.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Bargaining power of suppliers
    • 3.3.2. Bargaining power of buyers
    • 3.3.3. Threat of substitutes
    • 3.3.4. Threat of new entrants
    • 3.3.5. Intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. High prevalence of musculoskeletal (MSK) disorders
      • 3.4.1.2. Surge in geriatric population across the globe
      • 3.4.1.3. Increase in number of pipeline drugs
    • 3.4.2. Restraints
      • 3.4.2.1. Lack of treatment in emerging countries
    • 3.4.3. Opportunities
      • 3.4.3.1. High growth potential in emerging markets
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DRUG TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Analgesics
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. DMARDs
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Corticosteroids
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Others
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country

CHAPTER 5: MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY ROUTE OF ADMINISTRATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Oral
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Parenteral
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital Pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Online Providers
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Drug Stores and Retail Pharmacies
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: MUSCULOSKELETAL DISORDERS DRUGS MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Drug Type
    • 7.2.3. Market size and forecast, by Route of Administration
    • 7.2.4. Market size and forecast, by Distribution Channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Drug Type
      • 7.2.5.1.3. Market size and forecast, by Route of Administration
      • 7.2.5.1.4. Market size and forecast, by Distribution Channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Drug Type
      • 7.2.5.2.3. Market size and forecast, by Route of Administration
      • 7.2.5.2.4. Market size and forecast, by Distribution Channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Drug Type
      • 7.2.5.3.3. Market size and forecast, by Route of Administration
      • 7.2.5.3.4. Market size and forecast, by Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Drug Type
    • 7.3.3. Market size and forecast, by Route of Administration
    • 7.3.4. Market size and forecast, by Distribution Channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Drug Type
      • 7.3.5.1.3. Market size and forecast, by Route of Administration
      • 7.3.5.1.4. Market size and forecast, by Distribution Channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Drug Type
      • 7.3.5.2.3. Market size and forecast, by Route of Administration
      • 7.3.5.2.4. Market size and forecast, by Distribution Channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Drug Type
      • 7.3.5.3.3. Market size and forecast, by Route of Administration
      • 7.3.5.3.4. Market size and forecast, by Distribution Channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Drug Type
      • 7.3.5.4.3. Market size and forecast, by Route of Administration
      • 7.3.5.4.4. Market size and forecast, by Distribution Channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Drug Type
      • 7.3.5.5.3. Market size and forecast, by Route of Administration
      • 7.3.5.5.4. Market size and forecast, by Distribution Channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Drug Type
      • 7.3.5.6.3. Market size and forecast, by Route of Administration
      • 7.3.5.6.4. Market size and forecast, by Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Drug Type
    • 7.4.3. Market size and forecast, by Route of Administration
    • 7.4.4. Market size and forecast, by Distribution Channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Drug Type
      • 7.4.5.1.3. Market size and forecast, by Route of Administration
      • 7.4.5.1.4. Market size and forecast, by Distribution Channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Drug Type
      • 7.4.5.2.3. Market size and forecast, by Route of Administration
      • 7.4.5.2.4. Market size and forecast, by Distribution Channel
      • 7.4.5.3. Australia
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Drug Type
      • 7.4.5.3.3. Market size and forecast, by Route of Administration
      • 7.4.5.3.4. Market size and forecast, by Distribution Channel
      • 7.4.5.4. India
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Drug Type
      • 7.4.5.4.3. Market size and forecast, by Route of Administration
      • 7.4.5.4.4. Market size and forecast, by Distribution Channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Drug Type
      • 7.4.5.5.3. Market size and forecast, by Route of Administration
      • 7.4.5.5.4. Market size and forecast, by Distribution Channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by Drug Type
      • 7.4.5.6.3. Market size and forecast, by Route of Administration
      • 7.4.5.6.4. Market size and forecast, by Distribution Channel
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Drug Type
    • 7.5.3. Market size and forecast, by Route of Administration
    • 7.5.4. Market size and forecast, by Distribution Channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Drug Type
      • 7.5.5.1.3. Market size and forecast, by Route of Administration
      • 7.5.5.1.4. Market size and forecast, by Distribution Channel
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Drug Type
      • 7.5.5.2.3. Market size and forecast, by Route of Administration
      • 7.5.5.2.4. Market size and forecast, by Distribution Channel
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by Drug Type
      • 7.5.5.3.3. Market size and forecast, by Route of Administration
      • 7.5.5.3.4. Market size and forecast, by Distribution Channel
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by Drug Type
      • 7.5.5.4.3. Market size and forecast, by Route of Administration
      • 7.5.5.4.4. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. AbbVie Inc.
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. Amgen Inc.
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
    • 9.2.7. Key strategic moves and developments
  • 9.3. Eli Lilly and Company
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
  • 9.4. F. Hoffmann-La Roche Ltd.
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
  • 9.5. Johnson & Johnson
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
    • 9.5.7. Key strategic moves and developments
  • 9.6. Merck & Co., Inc.
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
  • 9.7. Novartis AG
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
    • 9.7.7. Key strategic moves and developments
  • 9.8. Pfizer Inc.
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
    • 9.8.7. Key strategic moves and developments
  • 9.9. Teva Pharmaceutical Industries Ltd.
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
    • 9.9.7. Key strategic moves and developments
  • 9.10. UCB S.A.
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance